MedTrace Logo

Clinical Study to Evaluate the Anti-aging Efficacy and Skin Radiance-enhancing Effect of Dermial®.

NCT07790237 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2026-08-27

No results posted yet for this study

Summary

The present clinical study has been designed to evaluate the efficacy and safety of Dermial® at a daily dose of 60 mg on skin brightness, hydration, luminosity and other signs of facial skin aging in healthy women aged 35 to 65 years presenting physiological age-related skin aging, compared with placebo over a 12-week supplementation period.

Conditions

  • Healthy Adult Females

Interventions

DIETARY_SUPPLEMENT

DERMIAL

1 cap 60 mg/day

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • IMDA - Instituto de Medicina y Dermatología Avanzada

    collaborator UNKNOWN

  • Bioiberica

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-14
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07790237 on ClinicalTrials.gov